The hormone-receptor-positive Luminal A and Luminal B molecular subtypes of clinical breast cancer respond to selective estrogen-receptor modulators, aromatase inhibitors, and to HER-2 targeted therapeutics. Here, CYP19A1 is linked to breast carcinoma.